A reminder amid the social media peptide wave that most products online lack the approval and trial data behind GLP-1 medicines.
Recap by typeshit. Post by Facebook on Facebook.
One study cited by @fittrwithsquats put the risk of non-scarring hair loss about 40% higher with GLP-1 use, mostly telogen effluvium. Nail findings are less consistent.
European regulators first raised NAION, a rare optic nerve condition sometimes called an eye stroke, as a possible risk more than 15 months ago.
Obesity doctor Spencer Nadolsky takes on six popular misconceptions about Ozempic in a quick social video. The caption doesn't say which myths are covered.
Users described more appetite, fatigue, extra energy and insomnia. An analysis of Reddit comments, not a clinical trial, so the findings come from self-reports.
Dr Kazarian points out that retatrutide hasn't been approved yet, so he says anyone using it now isn't getting the genuine drug from Lilly.
Novo, Lilly and Zealand showed amylin trial data in Milan. CagriSema hit 22.4% average weight loss in a trial and has an FDA decision expected by year end.
Loading…